- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Displacement.
Displaying page 1 of 2.
EudraCT Number: 2014-000707-28 | Sponsor Protocol Number: FODANKEL01 | Start Date*: 2014-07-04 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: Displacement of popliteal sciatic nerve catheters after major foot and ankle surgery. Long axis (LAX) compared with short axis (SAX), a MR/US image fusion study | ||||||||||||||||||
Medical condition: The medical condition to be examined in this study, is postoperative pain after major foot and ankle surgery. Which way to insert a sciatic nerve catheter to treat postoperative pain is the most ef... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003932-40 | Sponsor Protocol Number: 1138.11 | Start Date*: 2009-03-26 | |||||||||||
Sponsor Name:Boerhinger Ingelheim Pharma GmbH & Co.KG | |||||||||||||
Full Title: A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients suff... | |||||||||||||
Medical condition: chronic venous insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001360-36 | Sponsor Protocol Number: LF-DML-MS | Start Date*: 2013-09-30 |
Sponsor Name:ULB - Unité de Recherche en Lymphologie - Faculté des Sciences de la motricité | ||
Full Title: Evaluation of the benefit of lymphofluoroscopy in the validation of the manual drainage techniques on lymphedema | ||
Medical condition: upper limb lymphedema | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000043-74 | Sponsor Protocol Number: PNAS0122 | Start Date*: 2023-07-27 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications | ||
Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003771-20 | Sponsor Protocol Number: BI 1138.10 | Start Date*: 2006-02-09 | |||||||||||
Sponsor Name:Boehringer Ingelheim GmbH | |||||||||||||
Full Title: A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suf... | |||||||||||||
Medical condition: chronic venous insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000163-89 | Sponsor Protocol Number: COG0104 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a... | |||||||||||||
Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003625-15 | Sponsor Protocol Number: Cath_TQL_caesarean_version1 | Start Date*: 2018-06-22 | ||||||||||||||||
Sponsor Name:Zealand university hospital, Roskilde | ||||||||||||||||||
Full Title: Ultrasound-guided Transmuscular Quadratus Lumborum catheters for elective caesarean section. A double blind, randomised, placebo controlled trial. | ||||||||||||||||||
Medical condition: Treatment of postoperative pain after elective caesarean section. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000421-13 | Sponsor Protocol Number: 1913 | Start Date*: 2017-07-27 |
Sponsor Name:Erasmus MC | ||
Full Title: Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial | ||
Medical condition: Congenital diaphragmatic hernia with pulmonary hypertension | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) NO (Prematurely Ended) AT (Prematurely Ended) SE (Ongoing) BE (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013391-44 | Sponsor Protocol Number: EDX09/01 | Start Date*: 2010-02-05 | |||||||||||
Sponsor Name:OM PHARMA SA | |||||||||||||
Full Title: Multicentre, double blind, placebo-controlled, randomised clinical study to assess the efficacy and safety of Doxium® 500 three times daily in patients suffering from chronic venous insufficiency (... | |||||||||||||
Medical condition: Chronic Venous Insufficiency (CVI) CEAP Class C3 or C4 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001634-28 | Sponsor Protocol Number: CVMD-DU-087 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedema | |||||||||||||
Medical condition: Patients with Type 2 diabetes mellitus (T2DM) whoa re not receiving insulin treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002835-14 | Sponsor Protocol Number: SCCCSH01 | Start Date*: 2016-10-07 | |||||||||||
Sponsor Name:Nordsjællands Hospital Hillerød | |||||||||||||
Full Title: Supraclavicular catheter for regional anesthesia of the shoulder - an explorative study in healthy volunteers. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018637-21 | Sponsor Protocol Number: 1 | Start Date*: 2013-11-20 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein UKSH | ||||||||||||||||||
Full Title: Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrha... | ||||||||||||||||||
Medical condition: exsudative age-related macular degeneration with acut submacular hemorrhage | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003395-72 | Sponsor Protocol Number: VitD@BPPV | Start Date*: 2016-11-29 |
Sponsor Name:Hospital of the University of Munich | ||
Full Title: Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV) | ||
Medical condition: The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004145-16 | Sponsor Protocol Number: Z7219K01 | Start Date*: 2019-07-24 | |||||||||||
Sponsor Name:Zambon SpA | |||||||||||||
Full Title: A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients w... | |||||||||||||
Medical condition: Parkinsonian variant of Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001832-34 | Sponsor Protocol Number: 3100N7-211-WW | Start Date*: 2007-01-11 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-of-Care Controlled, Feasibility and Safety Study of rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal Femur | |||||||||||||
Medical condition: Closed fracture of the proximal femur | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) HU (Completed) FR (Completed) SE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014359-63 | Sponsor Protocol Number: CSPA100A2201 | Start Date*: 2010-01-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate... | |||||||||||||
Medical condition: hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000174-25 | Sponsor Protocol Number: 101090401IN | Start Date*: 2023-03-17 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehi... | |||||||||||||
Medical condition: Fuchs Endothelial Corneal Dystrophy (FECD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002348-33 | Sponsor Protocol Number: A35-011 | Start Date*: 2022-12-22 | |||||||||||
Sponsor Name:Amylyx Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Stud... | |||||||||||||
Medical condition: ALS (amyotrophic lateral sclerosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Completed) IT (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) BE (Completed) PT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013702-14 | Sponsor Protocol Number: BETNV009 | Start Date*: 2010-08-13 | ||||||||||||||||
Sponsor Name:Hospital of the University of Munich | ||||||||||||||||||
Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial | ||||||||||||||||||
Medical condition: vestibular failure (vestibular neuritis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002088-29 | Sponsor Protocol Number: DFR2593-307 | Start Date*: 2007-08-22 | |||||||||||
Sponsor Name:Rheoscience A/S | |||||||||||||
Full Title: Efficacy and Safety of Treatment with Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy | |||||||||||||
Medical condition: Balaglitazone is being developed as an oral anti-diabetic drug to improve glycaemic control in patients with type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
